Pfizer Limited reported robust Q3 FY26 results with revenue rising nearly 20% year-on-year to 645 crore rupees and net profit climbing 11% to 141.8 crore rupees. EBITDA surged 56% to 228.3 crore rupees, driving margins higher. The performance reflects strong demand across therapy areas and improved cost efficiencies.
Pfizer Limited delivered a solid set of financial results for the quarter ended December 31, 2025, showcasing healthy topline growth and improved profitability. The company’s operating leverage and efficiency gains contributed to a sharp margin expansion, reinforcing its strong position in the Indian pharmaceutical market.
Key Highlights
-
Revenue grew 19.9% YoY to 645 crore rupees, compared to 538 crore rupees last year
-
Net profit rose 11.1% YoY to 141.8 crore rupees, up from 127.6 crore rupees
-
EBITDA surged 55.8% YoY to 228.3 crore rupees, versus 146.5 crore rupees in Q3 FY25
-
Operating margins expanded to 35.4% from 27.2% in the prior year quarter
-
Total income for the quarter stood at 683.24 crore rupees
-
Shares of Pfizer Limited closed at 4,770 rupees on NSE, up 3.91% ahead of the earnings announcement
The results underline Pfizer’s ability to sustain growth momentum while enhancing profitability through operational efficiencies and strong demand across therapy areas.
Sources: CNBC TV18, InvestyWise